ETAS ID: TM761071

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
SCPHARMACEUTICALS INC.		10/13/2022	Corporation: DELAWARE

RECEIVING PARTY DATA

Name:	OAKTREE FUND ADMINISTRATION, LLC		
Street Address:	333 S. Grand Avenue, 28th Fl.		
Internal Address:	Attn: Oaktree Agency		
City:	Los Angeles		
State/Country:	CALIFORNIA		
Postal Code:	90071		
Entity Type:	Limited Liability Company: DELAWARE		

PROPERTY NUMBERS Total: 5

Property Type	Number	Word Mark	
Serial Number:	97339038	SCPHARMACEUTICALS	
Registration Number:	5351975	SCPHARMACEUTICALS	
Registration Number:	4851675	SCPHARMACEUTICALS	
Registration Number:	5287573	FUROSCIX	
Registration Number:	5291840	SC2WEAR	

CORRESPONDENCE DATA

Fax Number: 2122919868

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (212) 558-4229

Email: demarcor@sullcrom.com, nguyenb@sullcrom.com

Raffaele A. DeMarco Correspondent Name: 125 Broad Street Address Line 1:

Address Line 2: Sullivan & Cromwell LLP

Address Line 4: New York, NEW YORK 10004-2498

ATTORNEY DOCKET NUMBER:	018392.00119 (RAD)
NAME OF SUBMITTER:	RAFFAELE A. DEMARCO
SIGNATURE:	/RAFFAELE A. DEMARCO/
DATE SIGNED:	10/13/2022

Total Attachments: 5

source=Saturn - Trademark Security Agreement (Executed) 4872-6029-4201 v.1#page1.tif

source=Saturn - Trademark Security Agreement (Executed) 4872-6029-4201 v.1#page2.tif

source=Saturn - Trademark Security Agreement (Executed) 4872-6029-4201 v.1#page3.tif

source=Saturn - Trademark Security Agreement (Executed) 4872-6029-4201 v.1#page4.tif

source=Saturn - Trademark Security Agreement (Executed) 4872-6029-4201 v.1#page5.tif

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT, dated as of October 13, 2022 ("Trademark Security Agreement"), made by each of the signatories hereto (the "Trademark Grantors"), is in favor of Oaktree Fund Administration, LLC, as administrative agent for the Secured Parties (in such capacity, together with its successors and assigns, the "Administrative Agent").

WITNESSETH:

WHEREAS, the Trademark Grantors are party to a Security Agreement, dated as October 13, 2022 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the "Security Agreement") in favor of the Administrative Agent, pursuant to which the Trademark Grantors are required to execute and deliver this Trademark Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Security Agreement);

WHEREAS, pursuant to the terms of the Security Agreement, each Trademark Grantor has created in favor of the Administrative Agent a security interest in, and the Administrative Agent has become a secured creditor with respect to, the Trademark Collateral (as defined below);

NOW, THEREFORE, in consideration of the premises and to induce the Administrative Agent and the Lender to enter into the Credit Agreement and to induce the Lender to make their respective extensions of credit to the Borrower thereunder, each Trademark Grantor hereby grants to the Administrative Agent, for itself and on behalf of and for the ratable benefit of the other Secured Parties, a security interest in all of the following property now owned or at any time hereafter acquired by such Trademark Grantor or in which such Trademark Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the "*Trademark Collateral*"), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:

- (a) all Trademarks of such Trademark Grantor, including, without limitation, the registered and applied-for Trademarks of such Trademark Grantor listed on **Schedule 1** attached hereto; <u>provided</u>, that no Lien or security interest is granted hereunder with respect to any United States "intent-to-use" trademark or service mark application filed pursuant to Section 1(b) of the Lanham Act prior to the filing of an "Amendment to Allege Use" or a "Statement of Use" pursuant to Sections 1(c) or 1(d) of the Lanham Act, solely to the extent that, and only for so long as, the grant of a security interest therein would impair the validity or enforceability of, render void or voidable, or result in the cancellation of, such "intent-to-use" trademark or service mark application under applicable federal Law;
- (b) to the extent not covered by **clause** (a), all income, fees, royalties, damages or other payments now or hereafter due and payable with respect to any of the foregoing;
- (c) to the extent not covered by **clause** (a), the goodwill of the businesses with which the Trademarks are associated; and

(d) to the extent not covered by **clause** (a), all causes of action for past, present, or future infringement or other violation of any of the Trademarks or unfair competition regarding the same.

The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Security Agreement, and the Trademark Grantors hereby acknowledge and affirm that the rights and remedies of the Administrative Agent with respect to the security interest in the Trademarks made and granted hereby are more fully set forth in the Security Agreement. In the event that any provision of this Trademark Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

Each Trademark Grantor hereby authorizes and requests that the Commissioner of Trademarks record this Trademark Security Agreement.

THIS TRADEMARK SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS TRADEMARK SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES.

This Trademark Security Agreement may be executed by one or more of the parties to this Trademark Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Trademark Security Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.

[Remainder of This Page Intentionally Left Blank.]

2

IN WITNESS WHEREOF, each Trademark Grantor has caused this TRADEMARK SECURITY AGREEMENT to be executed and delivered by its duly authorized officer as of the date first above written.

SCPHARMACEUTICALS INC.

By:	"/him 74
	Name: John Tucker
	Title: President and Chief Executive Officer
Address	2400 District Ave., Suite 310
	Burlington, CA 01803

Accepted and Agreed:

OAKTREE FUND ADMINISTRATION,

LLC, as Administrative Agent

By: Oaktree Capital Management, L.P.

Managing Member Its:

xesua combosils By:

Jessiea Dombroff Name:

Vice President Title:

OcuSigned by:

By: Name: Brian Price

Title: Senior Vice President

Address for Notices:

Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Oaktree Agency

Email: Oaktreeagency@alterdomus.com

With copies to:

Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071

Attn: Stephen DeNelsky; Rahul Anand Email: SDeNelsky@oaktreecapital.com;

RAnand@oaktreecapital.com

and

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attn: Ari B. Blaut

Tel.: (212) 558-1656

Schedule 1

TRADEMARKS

Trademark Registrations and Applications

Trademark	Jurisdiction	Application No. Filing Date	Registration No. Registration Date	Record Owner
SCPHARMACEUTICALS	US	97339038 March 30, 2022		scPharmaceuticals Inc.
scPharmaceuticals	US	87292049 January 6, 2017	5351975 December 5, 2017	scPharmaceuticals Inc.
scPharmaceuticals	US	85983858 February 11, 2013	4851675 November 10, 2015	scPharmaceuticals Inc.
FUROSCIX	US	87101278 July 12, 2016	5287573 September 12, 2017	scPharmaceuticals Inc.
sc2Wear	US	86869799 January 8, 2016	5291840 September 19, 2017	scPharmaceuticals Inc.

RECORDED: 10/13/2022